Cat | Cas | Eng
Previous issues
Digital newsletter of IDIBELL
Number 141 - 11 May 2015

¿Discovered the sixth DNA's base?

The director of the Epigenetics and Cancer Biology Program at IDIBELL, Manel Esteller, publishes today an article in Cell that suggests the existence of a sixth DNA's base: the methyl-adenine that would regulate the expression of certain genes in eukaryotic cells and which could have a specific role in stem cells and in early stages of development.

[+ info]
Eduard Montanya, new Scientific Director of the CIBER of Diabetes and Associated Metabolic Diseases

Eduard Montanya, CIBERDEM researcher and head of the research group on diabetes, nutrition and endocrine diseases at the Institute of Biomedical Research of Bellvitge (IDIBELL), has been appointed Scientific Director of CIBERDEM the Standing Committee of CIBER, under the Institute of Health Carlos III, on Monday April 27. Montanya has relieved Dr. Luis Castaño, who occupied this position since 2012.

[+ info]
A new and less toxic HIV drug

University Hospital of Bellvitge and IDIBELL have participated in an international study published in The Lancet that has evaluated a new drug with fewer negative long-term effects that one of the most used so far in treating HIV. Today, it would be beneficial for around 65% of patients with HIV

[+ info]
Nutrition and cancer at 'Pessics' of science

On April 15 the Bellvitge Library hosted the lecture "Cancer and Nutrition" by Antonio Agudo, head of the Unit of Nutrition, Environment and Cancer of the ICO-IDIBELL and specialist in preventive medicine and public health. The conference is part of the series 'Pessics de Ciència' organized by the Sant Josep Cultural Centre L'Hospitalet de Llobregat.

[+ info]
Identified a novel therapeutic target for type of colorectal cancer with poor prognosis

Researchers at the Hospital del Mar Institute of Medical Research (IMIM) in collaboration with researchers from IDIBELL and the Catalan Institute of Oncology have identified a new way of treating colorectal cancer. In the study published in the journal Science Signaling researchers have shown that inhibition of endosomal activity is a potential therapeutic strategy for the treatment of cancers with mutated BRAF gene. 

[+ info]
Fernando Fernández-Aranda, Leadership Award on Research 2015of the Academy for Eating Disorders

The group leader pf the Biomedical Research Center in Red-Pathophysiology of Obesity and Nutrition, who heads the unit Disorders Eating Disorders at the University Hospital of Bellvitge and who is is part of the research group in Psychiatry at the IDIBELL, has received this recognition, awarded by the Academy for Eating Disorders, the largest international scientific society in the field of Eating Disorders, for his extensive work in this field.

[+ info]
Previous news
Cannabis Consumers Show Greater Susceptibility to False Memories
Manel Esteller awarded the Dr. Josep Trueta Medal of Health Merit of the Generalitat of Catalonia
Supercomputing for biomedical research
When genes are expressed in reverse: Discovered a regulatory mechanism of antisense DNA
Researchers discover an inactive tumor suppressor gene in lung cancer
IDIBELL participates in a program led by ICFO to develop new clinical tools through photonics
The director of IDIBELL, Jaume Reventós, at the second charity dinner of AECC Tarragona
Olga Torres Foundation funds a research project in colon cancer IDIBELL
Prolonged exposure to certain pesticides and detergents increase the risk of lymphoma
Events and meetings
IDIBELL Seminars. Mireia Caralt: “Bioengenyeria i regeneració de teixits”
SpecialSeminars. Stephen P. Schoenberger: ''Helping the anti-tumour CD8+ T cell response''
El Punt Avui - Una nova base de I’ADN?
El País - El ADN está escrito con seis ‘letras’ y no con las cuatro más conocidas
Gaceta Médica - Eduard Montanya, nuevo director científico del Ciber de Diabetes y Enfermedades Metabólicas
Diario Médico - La metil-adenina (mA) podría ser la sexta base del ADN
El Periódico de Catalunya - Suplement Salut - Els ratolins, models per reproduir tumors humans
Communication Department
Institut d'Investigació Biom├Ędica de Bellvitge
93 260 71 29
93 260 72 82
Follow us:
Share with a friend:
By e-mail

Legal notice | Contact